Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.81 |
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
| ▸ | PGR | P06401 | 2/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CD69 | Q07108 | 1/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.39 |
| ▸ | IGF2R | P11717 | 2/20 | 0.38 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14612261 | 1.00 | NOD2 (0.81) | NOD2ESR1PGRHTR1AADORA3 | |
| Muramyldipeptide SCHEMBL17299289 | 0.90 | NOD2 (1.00) | NOD2ESR1PGRHTR1AADORA3 | |
| Muramyldipeptide SCHEMBL20516502 | 0.90 | NOD2 (1.00) | NOD2ESR1PGRHTR1AADORA3 | |
| Muramyldipeptide SCHEMBL41814 | 0.90 | NOD2 (1.00) | NOD2ESR1PGRHTR1AADORA3 | |
| Muramyl Dipeptide SCHEMBL9770111 | 0.90 | NOD2 (1.00) | NOD2ESR1PGRHTR1AADORA3 | |
| Muramyldipeptide SCHEMBL9231355 | 0.90 | NOD2 (1.00) | NOD2ESR1PGRHTR1AADORA3 | |
| Muramyldipeptide SCHEMBL19486934 | 0.90 | NOD2 (1.00) | NOD2ESR1PGRHTR1AADORA3 | |
| Muramyldipeptide SCHEMBL20516503 | 0.90 | NOD2 (1.00) | NOD2ESR1PGRHTR1AADORA3 | |
| Muramyldipeptide SCHEMBL15263102 | 0.90 | NOD2 (1.00) | NOD2ESR1PGRHTR1AADORA3 | |
| Muramyl Dipeptide SCHEMBL41813 | 0.90 | NOD2 (1.00) | NOD2ESR1PGRHTR1AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 696 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582711-B2 | RNA-based adjuvant to enhance the immune response to vaccines and therapeutics | ImmuneSure LLC (US) | 2026-03-24 | — | — | US | claimed |
| EP-4665387-A2 | TRYPTOPHAN NEOANTIGEN PEPTIDES FOR DIAGNOSTICS, THERAPEUTICS, AND VACCINES | Calviri, Inc. (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250360199-A1 | IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE | US HEALTH (US) | 2025-11-27 | — | — | US | claimed |
| EP-4551247-A1 | IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-05-14 | — | — | EP | claimed |
| EP-4487869-A2 | RNA ENCODING A TUMOR ANTIGEN | CureVac SE (DE) | 2025-01-08 | — | — | EP | claimed |
| EP-4445146-A2 | EXON 1 FRAMESHIFT ANTIGENS FOR VACCINES, THERAPEUTICS, AND DIAGNOSTICS | Arizona Board of Regents on behalf of Arizona State University (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2024206399-A2 | NON-CODING RNA PEPTIDE ANTIGENS FOR CANCER VACCINES, THERAPEUTICS, AND DIAGNOSTICS | CALVIRI, INC. (US) | 2024-10-03 | — | — | WO | claimed |
| US-20240310380-A1 | EXON 1 FRAMESHIFT ANTIGENS FOR VACCINES, THERAPEUTICS, AND DIAGNOSTICS | UNIV ARIZONA STATE (US) | 2024-09-19 | — | — | US | claimed |
| WO-2024173551-A2 | TRYPTOPHAN NEOANTIGEN PEPTIDES FOR DIAGNOSTICS, THERAPEUTICS, AND VACCINES | CALVIRI, INC. (US) | 2024-08-22 | — | — | WO | claimed |
| US-12018252-B2 | Methods and compositions for identifying neoantigens for use in treating cancer | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-06-25 | — | — | US | claimed |
| CN-115243712-A | Use of membrane inhibitors to facilitate development of vaccines against enveloped viruses | 康奈尔大学 | 2022-10-25 | — | — | CN | claimed |
| EP-3630131-B1 | A METHOD TO CREATE PERSONALIZED CANINE CANCER VACCINES | UNIV ARIZONA STATE (US) | 2022-08-31 | — | — | EP | claimed |
| US-20220257701-A1 | METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN TREATING AND PREVENTING CANCER | UNITED STATES GOVERNMENT | 2022-08-18 | — | — | US | claimed |
| EP-4038222-A1 | METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN TREATING AND PREVENTING CANCER | Arizona Board of Regents on behalf of Arizona State University (US) | 2022-08-10 | — | — | EP | claimed |
| US-11406698-B2 | Vaccine compositions | BHARAT BIOTECH INTERNATIONAL LIMITED (IN) | 2022-08-09 | — | — | US | claimed |
| US-20220211842-A1 | Methods and Devices for the Treatment of Food Allergies | TEXAS TECH UNIVERSITY SYSTEM | 2022-07-07 | — | — | US | claimed |
| WO-2022063858-A1 | IMMUNOMODULATORY COMPOUNDS AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | AC BIOSCIENCE SA (CH) | 2022-03-31 | — | — | WO | claimed |
| EP-3973986-A1 | IMMUNOMODULATORY COMPOUNDS AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | AC BioScience SA (CH) | 2022-03-30 | — | — | EP | claimed |
| US-20220040293-A1 | HCoV VACCINE FOR IMPROVING IMMUNITY AGAINST SARS-COV-2 INFECTION | MOORE TIMOTHY S (US) | 2022-02-10 | — | — | US | claimed |
| US-20220040291-A1 | HCoV VACCINE FOR IMPROVING IMMUNITY AGAINST SARS-COV-2 INFECTION | MOORE TIMOTHY S (US) | 2022-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582711-B2 | RNA-based adjuvant to enhance the immune response to vaccines and therapeutics | METTL16, RBM28, RBM26 | NOD2 2689/4885ESR1 1218/4885PGR 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.